Maddie Meyer/Getty Images News
Moderna (NASDAQ:MRNA) is targeting market approval of a personalized vaccine the company is developing with Merck (NYSE:MRK) for skin cancer in 2027, one of its top executives announced at an investor event on Wednesday.
However, Stephane Bancel, CEO of the COVID-19 vaccine